For five years, the company has researched how more than 17,000 adults who are overweight or obese and have cardiovascular disease reacted to Wegovy or a placebo. The trial tested the drug’s 2.4 milligram solution — the highest dosage approved for Wegovy after weekly increases from 0.25 milligrams.
The drug reduced cardiovascular events by 20 percent compared to the placebo group, Novo Nordisk said, and the solution was safe and effective.
The company said it plans to file approval documents in 2023 in seeking broader indication for the approved drug.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.